Cargando…
Treatment of Recurrent Focal Segmental Glomerulosclerosis in Pediatric Kidney Transplant Recipients: Effect of Rituximab
Recurrence of focal segmental glomerulosclerosis (FSGS) after renal transplantation is a complication that often leads to graft loss. There is no consensus on the optimal treatment of recurrent FSGS. Rituximab, a monoclonal antibody to CD20, may be a useful treatment of this complication. Methods. W...
Autores principales: | Sethna, Christine, Benchimol, Corinne, Hotchkiss, Hilary, Frank, Rachel, Infante, Lulette, Vento, Suzanne, Trachtman, Howard |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090748/ https://www.ncbi.nlm.nih.gov/pubmed/21577271 http://dx.doi.org/10.1155/2011/389542 |
Ejemplares similares
-
Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients
por: Park, Hoon Suk, et al.
Publicado: (2014) -
Focal Segmental Glomerulosclerosis and Recurrence in Living Donor Recipients
por: Mang, Josef, et al.
Publicado: (2021) -
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design
por: Trachtman, Howard, et al.
Publicado: (2011) -
Rituximab treatment of adults with primary focal segmental glomerulosclerosis
por: Wang, Liuwei, et al.
Publicado: (2023) -
Rituximab for plasma exchange-dependent recurrent focal segmental glomerulosclerosis after renal transplantation
por: Deegens, Jeroen K. J., et al.
Publicado: (2008)